Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $37,260 | 21 | 88.3% |
| Travel and Lodging | $4,065 | 18 | 9.6% |
| Food and Beverage | $863.34 | 30 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $9,622 | 16 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $9,015 | 9 | $0 (2017) |
| Mallinckrodt LLC | $5,370 | 2 | $0 (2017) |
| GlaxoSmithKline, LLC. | $4,750 | 1 | $0 (2020) |
| Blueprint Medicines Corporation | $4,500 | 1 | $0 (2021) |
| Eli Lilly and Company | $3,771 | 24 | $0 (2019) |
| BeiGene USA, Inc. | $3,500 | 1 | $0 (2022) |
| Janssen Research & Development, LLC | $1,546 | 14 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $114.66 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $3,973 | 2 | BeiGene USA, Inc. ($3,500) |
| 2021 | $9,635 | 4 | Incyte Corporation ($5,020) |
| 2020 | $5,763 | 4 | GlaxoSmithKline, LLC. ($4,750) |
| 2019 | $4,648 | 27 | Eli Lilly and Company ($3,771) |
| 2018 | $687.36 | 2 | Incyte Corporation ($687.36) |
| 2017 | $17,483 | 30 | Novartis Pharmaceuticals Corporation ($9,015) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/17/2022 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $472.50 | General |
| Category: Hematology/Oncology | ||||||
| 06/08/2022 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 11/08/2021 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $270.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/06/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $114.66 | General |
| Category: Oncology | ||||||
| 04/05/2021 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 03/19/2021 | Blueprint Medicines Corporation | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 12/18/2020 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $202.50 | General |
| Category: Hematology/Oncology | ||||||
| 08/18/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 05/21/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $270.00 | General |
| 05/07/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| 11/21/2019 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 11/21/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $72.00 | General |
| 11/21/2019 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $29.00 | General |
| 11/21/2019 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $6.12 | General |
| 11/14/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $209.00 | General |
| 11/14/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $69.87 | General |
| 11/14/2019 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $40.78 | General |
| 11/14/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $31.59 | General |
| 11/14/2019 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $30.59 | General |
| 11/14/2019 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $23.63 | General |
| 11/14/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $20.90 | General |
| 11/14/2019 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $16.91 | General |
| 11/14/2019 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $14.63 | General |
| 11/14/2019 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $11.12 | General |
| 11/14/2019 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $10.20 | General |
About Dr. Michael Link, MD
Dr. Michael Link, MD is a Pediatric Hematology-Oncology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1982742862.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Link, MD has received a total of $42,188 in payments from pharmaceutical and medical device companies, with $3,973 received in 2022. These payments were reported across 69 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($37,260).
Practice Information
- Specialty Pediatric Hematology-Oncology
- Other Specialties Pediatrics
- Location Palo Alto, CA
- Active Since 02/02/2007
- Last Updated 04/16/2024
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1982742862
Products in Payments
- KYMRIAH (Biological) $9,015
- JAKAFI (Drug) $1,632
- IMBRUVICA (Drug) $1,546
- OPDIVO (Biological) $114.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Palo Alto
Philip Pizzo, Md, MD
Pediatric Hematology-Oncology — Payments: $2.6M
Christopher Dvorak, Md, MD
Pediatric Hematology-Oncology — Payments: $125,679
Dr. John Curnutte, M.d., Ph.d, M.D., PH.D
Pediatric Hematology-Oncology — Payments: $49,859
Bertil Glader, Md, MD
Pediatric Hematology-Oncology — Payments: $47,480
Glaivy Batsuli, Md, MD
Pediatric Hematology-Oncology — Payments: $43,490
Orly Klein, Md, MD
Pediatric Hematology-Oncology — Payments: $31,152